Dataset Information

Circulating cell populations as response predictors and targets to improve immunotherapy in metastatic lung cancer

ABSTRACT: Immunotherapy efficacy varies among patients with advanced non-small cell lung cancer (NSCLC). Here, we profiled baseline systemic immunity in patients with stage IV NSCLC treated with anti-PD-1 plus chemotherapy to identify immune mechanisms and circulating biomarkers associated with response. We prospectively enrolled 33 treatment-naive patients, including 22 responders and 11 non-responders at week 9, and 17 responders and 16 non-responders at 6 months. Responders showed increased frequencies of circulating T cells expressing CD69, TCF-1, and CXCR3. In contrast, non-responders exhibited higher frequencies of CTLA-4-, CD161-, and IL-10-expressing CD4+ and CD8+ T cells. These systemic immune profiles were mirrored in the tumor microenvironment in an independent cohort. Importantly, combined CTLA-4 and PD-1 blockade reactivated anti-tumor T cell features in non-responders in vitro, highlighting CTLA-4 as a potential driver of resistance. Together, these findings support personalized immunotherapy strategies guided by systemic immune biomarkers in advanced NSCLC.

ORGANISM(S): Homo sapiens

PROVIDER: GSE306542 | GEO | 2026/04/02

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Hepatocellular carcinoma (HCC) has dismal treatment responses to systemic therapies and is caused by both, viral and non-viral etiologies, including non-alcoholic steatohepatitis (NASH) 1–5. NASH - triggered by high caloric intake and sedentary lifestyle - has become an important driver for HCC development. Immunotherapy has been recently approved for HCC but stratification of responders versus non-responders has remained an unmet need 5–8. Here, we found a progressive accumulation of non-classical activated CD8+PD-1+ T-cells in livers of NASH-affected patients and mice. PD-L1/PD-1-targeted immunotherapy of NASH-induced HCC administered either at cancer-initiation or after cancer-establishment lacked beneficial effects in mice. On the contrary, PD-1-targeted immunotherapy drove hepatic necro-inflammation and increased liver cancer incidence, tumor number, and nodule size. Anti-CD8 or anti-CD8/anti-NK1.1 treatment suppressed liver cancer development, implicating CD8+ T-cells as liver cancer drivers in the context of NASH. In line, PD-1-/- mice challenged with a NASH-inducing diet displayed early-onset of liver cancer. Mechanistically, PD-1-targeted immunotherapy triggered necro-inflammation and a pro-tumorigenic environment in the context of NASH, increasing the abundance of hepatic TOX+CXCR6+ expressing CD8+PD-1+ TNF+ T-cells. Anti-CD8/anti-PD-1 or anti-TNF/anti-PD-1, but not anti-CD4/anti-PD-1 treatment reverted anti-PD1 treatment-related increase of liver inflammation, NASH severity and tumorigenesis. Gene expression profile and increased abundance of murine hepatic CD8+PD-1+ T-cells were corroborated in human CD8+PD-1+ T cells derived from NASH patients. In a meta-analysis of clinical trials testing PD-1-targeting immune checkpoint inhibitors alone (i.e. pembrolizumab) or in combination in 1656 patients with advanced HCC, immunotherapy was not favorable over to control treatment in non-viral- when compared to viral-related HCC. Similarly, in two clinical cohorts tested, patients with NASH-driven HCC had a significantly worse overall survival with PD-1-targeted immunotherapy than HCC patients with other etiologies. Our data identify non-viral etiologies, particularly NASH, as potentially non-responsive in the context of HCC immunotherapy, providing a strong rational basis for patient stratification.

Dataset Information

Circulating cell populations as response predictors and targets to improve immunotherapy in metastatic lung cancer

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets